Freyja Healthcare, LLC announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for VereSee™, its second-generation Mini Laparoscope with VisualEntry™ System. This clearance marks a significant milestone for the company, advancing its mission to bring visualization to the earliest stages of minimally invasive surgery.
VereSee is designed to integrate visualization directly into the laparoscopic entry process. It combines a miniature 2mm laparoscope with Freyja's VisualEntry™ System, allowing surgeons to see anatomical structures during the entry itself. This represents a departure from conventional techniques where initial abdominal access is often performed without direct visualization, potentially increasing the risk of complications.
“FDA clearance of VereSee is an incredibly important milestone for Freyja Healthcare,” said Mike MacKinnon, CEO of Freyja Healthcare. “We believe surgeons should have the ability to see when it matters most. VereSee brings visualization to the very beginning of the procedure while also providing the functionality of a miniature laparoscope, which may enable surgeons to avoid opening an additional laparoscope for certain procedures.”
The system is engineered around a simple yet profound concept: provide visualization during entry rather than waiting until after access has been established. Once access is achieved, VereSee can continue to serve as a miniature laparoscope for visualization, potentially eliminating the need for a separate scope in some cases. The device pairs single-use entry components with reusable visualization technology, creating a platform that integrates seamlessly into the laparoscopic workflow while supporting a practical economic model for healthcare providers.
VereSee was reviewed under the FDA's 510(k) premarket notification pathway and is classified as a Class II Endoscope and Accessories device. This clearance underscores the FDA's recognition of the device's safety and effectiveness for its intended use.
“VereSee represents more than a new method of laparoscopic entry,” said Jon I. Einarsson, MD, founder of Freyja Healthcare. “It is a miniature laparoscopic visualization platform that gives surgeons the opportunity to see anatomy from the moment of entry. We believe that has the potential to fundamentally change how surgeons think about access, while continuing to advance the miniaturization of laparoscopic visualization and scope functionality.”
The implications of this clearance are profound for the field of minimally invasive surgery. By enabling direct visualization during the entry step, VereSee could reduce the risk of vascular or bowel injuries, which are among the most serious complications of laparoscopic procedures. Furthermore, the ability to use the same miniature scope throughout the procedure may enhance efficiency and reduce costs by minimizing the need for multiple instruments.
With FDA clearance achieved, Freyja Healthcare will begin the commercial introduction of VereSee, expanding access to hospitals, ambulatory surgical centers, and surgeons performing minimally invasive procedures. This launch could accelerate the adoption of miniaturized visualization technologies and set a new standard for patient safety in laparoscopic surgery.
